Formononetin triggers ferroptosis in triple-negative breast cancer cells by regulating the mTORC1/SREBP1/SCD1 pathway
In conclusion, this study provides evidence that Formononetin exerts an anti-proliferative effect on triple-negative breast cancer by inducing ferroptosis. Moreover, the mTORC1-SREBP1 signal axis is identified as the primary mechanism through which formononetin exerts its therapeutic effects. These findings suggest that formononetin holds promise as a potential targeted drug for clinical treatment of TNBC.
Authors
- Shuangqin Huang (ORCID: https://orcid.org/0000-0001-5058-097X)
- Huan Wang (ORCID: https://orcid.org/0000-0002-5539-5893)
- Sheng Liu (ORCID: https://orcid.org/0000-0001-8203-9096)
- Dong Xie (ORCID: https://orcid.org/0000-0002-3715-1801)
- Tian Li (ORCID: https://orcid.org/0000-0002-1188-5727)
- Weihong Zhang (ORCID: https://orcid.org/0000-0003-0681-7751)
- Yulang Jiang
- Lingyi Zhu
Institutions
- Shanghai University of Traditional Chinese Medicine (CN)
- Yueyang Hospital (CN)
- Shanghai Traditional Chinese Medicine Hospital (CN)
- Community Health Center (US)
- Shuguang Hospital (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2024-09-27
- DOI
- https://doi.org/10.3389/fphar.2024.1441105
- Citations
- 15
- Primary Topic
- Ferroptosis and cancer prognosis
- Type
- article
- Field-Weighted Citation Impact
- 6.28
Funders
- Shanghai Municipal Health Commission
- Science and Technology Commission of Shanghai Municipality